The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -25,579 | -52,293 |
| Depreciation and amortization | 40 | 86 |
| Unrealized foreign currency gain | 0 | 0 |
| Stock-based compensation | 3,614 | 3,941 |
| Non-cash lease expense | 48 | 108 |
| Change in fair value of tranche rights | 0 | 0 |
| Fees expensed as part of january 2024 financing | 0 | 0 |
| Other current assets and prepaid expenses | -384 | 429 |
| Accounts payable | -31 | -896 |
| Accrued expenses | 1,428 | 3,447 |
| Operating lease liabilities | -50 | -118 |
| Other liabilities | 6 | -231 |
| Net cash used in operating activities | -20,140 | -46,385 |
| Purchases of property and equipment | 67 | 83 |
| Net cash used in investing activities | -67 | -83 |
| Proceeds from offering, net of issuance costs-May2025PIPETransaction | 0 | 60,661 |
| Proceeds from offering, net of issuance costs-April2025PIPETransaction | 0 | 4,734 |
| Proceeds from public offering of common stock through at the market sales agreement, net | 0 | 0 |
| Proceeds from offering, net of issuance costs-January2024PIPETransaction | 0 | 0 |
| Proceeds from shares issued in connection with the company's employee stock purchase plan | 0 | 123 |
| Net cash provided by financing activities | 0 | 65,518 |
| Effect of exchange rate changes on cash and cash equivalents | 29 | 592 |
| Net change in cash and cash equivalents | -20,178 | 19,642 |
| Cash and cash equivalents at beginning of period | 35,668 | - |
| Cash and cash equivalents at end of period | 35,132 | - |
IMMUNIC, INC. (IMUX)
IMMUNIC, INC. (IMUX)